So fortunate to share some Shakespearean moments with the incomparable Prof. Athol Wells at #ATS2024 in San Diego! 🫁😊 #MindOverMatter #pulmonaryfibrosis #ImagingBiomarkersAreKey #Glowing

This is amazing! Thank you from all of us at PF Warriors! #ATS2024

Dr. Katie Lee Katie Lee elegantly elaborates on exposures in ILD. • Tobacco and several non-tobacco job-type exposures show a strong relationship to ILD and have also been linked to ILAs! #ATS2024 PCCM UChicago

Dr. Kerri Johansson discusses challenges and possible solutions to exposure assessment. 🫁 Highlights several evidence-informed ILD questionnaires that can be leveraged in clinical practice. Much work remains to be done!!! #ATS2024 #PulmonaryFibrosis

Dr. Rachel Putman deftly navigates the issue of progression in ILAs and how well quantitative imaging identifies disease progression assessed variably by patterns and extent of disease. QIA changes predict progression of disease and mortality. #ATS2024

Dr. Bina Choi Bina Choi, MD discusses a proteomic signature of QIA validated in 2 large cohorts. Leveraged SHAP values which assesses rel. protein levels & contribution to QIA. Showed dynamic and sometimes linear relationship between proteins such as CRP, sRAGE and QIA. #ATS2024

Sarita Bergei B.S. navigates the novel EB-OCT tool and its potential utility in ILA progression. Nicely showed that subjects with microscopic honeycombing all had radiologic progression on follow up HRCT imaging!!! Amazing work! #ATS2024

Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that: • Progression of ILD is progression irrespective of time since diagnosis •“despite usual management” should be included in PPF definition Important for future PPF guidelines. #ATS2024

Dr. Aparna Swaminathan nicely discusses how EHR-acquired ILD diagnoses has the potential to elucidate progressive pulmonary fibrosis determination. Duke University Hospital #ATS2024 #ILD

Dr. Matt Koslow from National Jewish Health Medical Education beautifully outlines the utility of data-driven textural analysis in pulmonary fibrosis. Showed that the relationship between FVC and DTA indices is nuanced. #ATS2024

Dr. Thennapan discusses the development of a machine-learning based definition of PPF (progressive pulmonary fibrosis) and its potentially increased prognostic value. #ATS2024 #PPF #pulmonaryfibrosis #JustinOldham

It finally happened… (Re) introducing Dr. Deji Adegunsoye! • Ph.D. Genetics Genomics & Systems Biology🧬 • MSc. Public Health Sciences🏥 • Pulmonologist🫁 • Intensivist🩺 So grateful to all who helped on this journey. This one is for you. We did it!🎉 #PhDone #YesYouCan

Telomere length testing is a readily available clinical test for precision management of ILD. We describe the clinical impact of TL testing in ILD clinic including impact on pharmacologic management and genetic testing CHEST® Journal journal.chestnet.org/article/S0012-…

Our "Single Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis" is finally out!! It provides the first comprehensive #ImmuneILDCellAtlas in FHP with comparisons to IPF & controls. The 🧵about the paper is below: atsjournals.org/doi/10.1164/rc…

Deeply honored to contribute to the August 15 issue of The Blue Journal. My heartfelt thanks to the incredible team who enabled this. Together we continue to push the boundaries of knowledge in inflammation, fibrosis, genetics, & machine learning. Onward! #Grateful #Research

We delve into the profound clinical implications of genetic and genomic markers. We also explore opportunities for transformative change amidst existential challenges. Discover our insights and the path forward in our latest work at: atsjournals.org/doi/full/10.11…